Loading clinical trials...

Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB) | Clinical Trials | Clareo Health

RECRUITINGNA

Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)

Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB) EVANESCE-II

NCT07195656•FemPulse Corporation

View on ClinicalTrials.gov

Summary

A study to evaluate the safety and effectiveness of FemPulse System

Eligibility

Age

21 - No limit years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Females, defined as a person with a uterus and cervix, ≥21 years old, with a diagnosis of OAB and symptoms for more than 6 months, as confirmed by a physician. OAB is defined by urinary urgency, usually with urinary frequency and nocturia, with or without urgency urinary incontinence with symptoms
•Willing and able to comply with study required procedures and visits (e.g., maintaining consistent medication use, fluid intake, diary completion).

Exclusion Criteria

•Systemic condition or disease that may interfere with study participation (e.g., current systemic infection, uncontrolled autoimmune disease, uncontrolled immunodeficiency disease, history of myocardial infarction, etc.) as determined by study investigator.
•Not an appropriate study candidate as determined by investigator.

Locations (15)

Cedars Sinai

Beverly Hills, California, United States

UCLA

Los Angeles, California, United States

UC Irvine

Orange, California, United States

Stanford

Palo Alto, California, United States

USCD

San Diego, California, United States

Holy Cross Medical Group - Women's Center

Fort Lauderdale, Florida, United States

Comprehensive Urologic

Barrington, Illinois, United States

University of Louisville

Louisville, Kentucky, United States

Chesapeake Urology

Owings Mills, Maryland, United States

Minnesota Urology

Woodbury, Minnesota, United States

Key Dates

Start Date

September 30, 2025

Primary Completion Date

May 31, 2027

Completion Date

December 31, 2027

Last Updated

February 6, 2026

Enrollment

151

ESTIMATED participants

Conditions

Overactive Bladder (OAB)

Interventions

Device Group

DEVICE

Medication Group

DRUG

Contacts

Monica Unger

CONTACT

7275123718 monica.unger@moxieclinical.com

INOPASE - Performance and Safety Study of a Personalised SNM System

NCT07193407

Overactive Bladder (OAB)

View study

ENROLLING_BY_INVITATIONNA

Transcutaneous Tibial Nerve Stimulation Therapy in Children With Overactive Bladder

NCT06765629

Overactive Bladder (OAB)

View study

NOT_YET_RECRUITINGPHASE2

Evaluate the Safety and Efficacy of TRG-200 KIT in Patients With Refractory Overactive Bladder.

NCT07391878

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 6, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)

Inclusion Criteria

Exclusion Criteria

INOPASE - Performance and Safety Study of a Personalised SNM System

Transcutaneous Tibial Nerve Stimulation Therapy in Children With Overactive Bladder

Evaluate the Safety and Efficacy of TRG-200 KIT in Patients With Refractory Overactive Bladder.

Tensi+ for Treating Overactive Bladder: A Randomized Controlled Trial

BlueWind RENOVA iStim™ System for the Treatment of OAB

Cefar URO - Symptomatic Treatment of Overactive Bladder